# GALNT16

## Overview
The GALNT16 gene encodes the enzyme polypeptide N-acetylgalactosaminyltransferase 16, which belongs to the GALNT family of glycosyltransferases. This enzyme is primarily involved in the initiation of mucin-type O-glycosylation, a critical post-translational modification process that affects protein stability, signaling, and cell-cell interactions (Mueller2019Altered). GALNT16 is active in the Golgi apparatus, where it catalyzes the transfer of N-acetylgalactosamine to serine or threonine residues on target proteins (Chia2016Short). The enzyme plays a significant role in modulating TGF-β signaling pathways, which are crucial for various cellular processes and have been implicated in disorders such as schizophrenia (Mueller2019Altered). As a member of the evolutionarily conserved GALNT family, GALNT16 exhibits distinct substrate specificities, although it shares some functional overlap with other family members, allowing for potential compensatory mechanisms within cells (Mueller2019Altered).

## Function
The GALNT16 gene encodes an enzyme that is part of the GALNT family, which is involved in the initiation of O-GalNAc glycosylation, a common type of protein glycosylation in animals. This process is crucial for the modification of mucins and proteins with mucin-like domains, often referred to as mucin-type O-glycosylation (Mueller2019Altered). GALNT16 is specifically involved in the modulation of TGF-β signaling by interfering with Activin and BMP ligand-receptor binding, pathways known to be disrupted in schizophrenia (Mueller2019Altered). The enzyme is active in the Golgi apparatus, where it catalyzes the transfer of N-acetylgalactosamine to serine or threonine residues on proteins, influencing protein stability, signaling, and cell-cell interactions (Chia2016Short).

The GALNT family, including GALNT16, is evolutionarily conserved, with distinct yet overlapping substrate specificities that allow for cellular compensation if one isoenzyme is impaired (Mueller2019Altered). Despite the potential for other GALNT isoenzymes to compensate for reduced GALNT16 expression, it is likely that only a small subset of glycoproteins associated with these signaling pathways are affected by changes in GALNT16 levels (Mueller2019Altered).

## Clinical Significance
GALNT16 is associated with various pathological conditions, particularly in the context of cancer prognosis. It is categorized as a "Good Prognosis-associated" (GPA) gene, indicating that its expression is often linked to favorable outcomes in cancer patient cohorts (Pucci2022Glycosyltransferases). Although specific diseases directly resulting from mutations or alterations in GALNT16 are not detailed, its role in core O-glycosylation suggests it may influence cancer progression through its involvement with the Tn-antigen (Pucci2022Glycosyltransferases).

In the respiratory system, GALNT16 expression is dynamically regulated in response to lung infections and injuries. For instance, significant upregulation of GALNT16 is observed in mouse lungs treated with bleomycin, a model for studying pulmonary fibrosis, and in response to house dust mite exposure (Tian2023Dynamic). This suggests a potential role in the respiratory system's response to environmental and infectious challenges, although the specific clinical implications of these changes remain to be fully elucidated.

Overall, while GALNT16 is implicated in cancer prognosis and respiratory responses, further research is needed to clarify its precise clinical significance and potential as a therapeutic target.


## References


[1. (Tian2023Dynamic) E Tian, Zulfeqhar A Syed, Matthew L Edin, Darryl C Zeldin, and Kelly G Ten Hagen. Dynamic expression of mucins and the genes controlling mucin-type o-glycosylation within the mouse respiratory system. Glycobiology, April 2023. URL: http://dx.doi.org/10.1093/glycob/cwad031, doi:10.1093/glycob/cwad031. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/glycob/cwad031)

[2. (Pucci2022Glycosyltransferases) Michela Pucci, Martina Duca, Nadia Malagolini, and Fabio Dall’Olio. Glycosyltransferases in cancer: prognostic biomarkers of survival in patient cohorts and impact on malignancy in experimental models. Cancers, 14(9):2128, April 2022. URL: http://dx.doi.org/10.3390/cancers14092128, doi:10.3390/cancers14092128. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers14092128)

3. (Mueller2019Altered) Altered protein expression of galactose and N-acetylgalactosamine transferases in schizophrenia superior temporal gyrus. This article has 4 citations.

[4. (Chia2016Short) Joanne Chia, Germaine Goh, and Frederic Bard. Short o-galnac glycans: regulation and role in tumor development and clinical perspectives. Biochimica et Biophysica Acta (BBA) - General Subjects, 1860(8):1623–1639, August 2016. URL: http://dx.doi.org/10.1016/j.bbagen.2016.03.008, doi:10.1016/j.bbagen.2016.03.008. This article has 103 citations.](https://doi.org/10.1016/j.bbagen.2016.03.008)